Denmark· DK-28106947823
Enzalutamide "Sandoz"
A enzalutamide product containing enzalutamid, registered in Denmark by Sandoz A/S. The same ATC class is registered in 16 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Enzalutamide is registered in 16 of 19 countries.
Countries holding a registration under ATC L02BB04 (enzalutamide), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 9 of them publish a price we can compare per daily dose
Enzalutamide · ATC L02BB04
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of enzalutamide costs, country by country.
Normalised to the WHO defined daily dose (0.16 g), the median price runs from $0.46 in France to $135.12 in Switzerland — a ×295 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Enzalutamide · price per daily dose (0.16 g)
USD · FX 28 Sept 2026
- CH Switzerland$135.12
- FR France$0.46
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- Enzalutamid
- Manufacturer
- Sandoz A/S
- Country
- Denmark (DK)
- ATC code
- L02BB04
- ATC class
- Enzalutamide
- Defined daily dose
- 0.16 g, O
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28106947823
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
706 interactions on record for enzalutamide.
Graded by severity as the source publishes them — 241 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Enzalutamide · interactions on record
706 records
- 241 severe
- 448 moderate
- 17 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- RolapitantA04AD14severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L02BB04
Enzalutamide, as other registers publish it.
- GermanyEnzalutamid AccordAccord Healthcare B.V.
- GermanyEnzalutamid AlAliud Pharma Gmbh
- GermanyEnzalutamid HexalHexal Ag
- GermanyEnzalutamid HexalAdalvo Limited
- GermanyEnzalutamid RatiopharmRatiopharm Gmbh
- PolandEnzalutamid SandozSandoz Polska Sp. z o.o.
- PolandEnzalutamid SandozSandoz Polska Sp. z o.o.
- CzechiaENZALUTAMID SANDOZSandoz s.r.o., Praha
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/fd7d23ed-ce40-426a-a4b3-27506e4d4df7 GET /v1/drugs/fd7d23ed-ce40-426a-a4b3-27506e4d4df7?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "filmovertrukne tabletter",
"source": "dkma",
"strength": "40 mg",
"auth_role": "CMS",
"dk_drugid": "28106947823",
"substance": "Enzalutamid",
"auth_procedure": "MRP",
"in_medicinpriser": false,
"registration_date_serial": "45180"
}See everything about enzalutamide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.